The U.S. Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval for Calypso Medical Technologies, Inc.’s clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery. Investigators in the United States will implant three anchored Beacon® transponders in patients’ lungs and use the Calypso® System to precisely track tumor location and movement during lung cancer radiation therapy.Calypso’s electromagnetic technology is the only non-ionizing guidance solution that uses internal markers to keep the radiation beam precisely focused on the tumor in real-time, without adding unnecessary radiation. Used in prostate cancer radiation therapy, the Calypso System has been used to treat more than 10,000 patients worldwide.Learn more from Calypso.
About the Author
Interference Technology
Established in 1970, Interference Technology helps EMI/EMC engineers find solutions to their various testing, design, application and regulatory issues by publishing articles, news and other practical content. We help suppliers in these areas to find the right customers for their components, materials, test equipment and services through a wide range of marketing services, including lead generation, branding, market research and events. The publication is available in various printed and electronic media formats, with readers in over 60 countries. We also publish issues in local languages in China, Japan and Europe.